Can AI really cure all diseases?
THE SO WHAT
The real shift in AI-for-health isn’t a promise to ‘cure all diseases’—it’s the compression of hypothesis, design, and validation cycles across drug discovery and diagnostics. Operators in health and adjacent data businesses should be mapping where they sit in that loop, because value will accrue to whoever controls the highest-leverage data and feedback channels.
READ THE SOURCE
MORE FROM THE WIRE
Deep & Emerging TechQuantum mechanics once baffled scientists. Now it's changing the world
Quantum mechanics has already escaped the lab — from sensing to materials to early quantum computing — and the next wave targets energy, medicine, and simulation. If your roadmap touches optimization, chemistry, or secure comms on a 5–10 year horizon, you should at least map where quantum-native approaches could undercut your current assumptions.
Deep & Emerging TechUK parents warned against posting children’s photos publicly as AI abuse imagery surges
The surge in AI-generated child abuse imagery is forcing a reset on what “public” family content is acceptable online. Platforms and consumer apps that touch images of minors will face rising expectations for default protections, detection, and data minimization, not just terms-of-service language.
Deep & Emerging TechSK Hynix Seeks Access to AI Investors in $29 Billion US Listing
A $29 billion US listing for SK Hynix is another step in financializing the AI supply chain—memory is being treated as a direct AI exposure, not a cyclical commodity. Operators should expect tighter, more expensive memory markets and start designing for bandwidth and capacity constraints now.
Deep & Emerging TechSemiconductor Stocks Slide Amid AI Spending Concerns
Public markets are starting to question whether current AI capex levels are sustainable beyond 2026 even as hyperscalers keep signing checks. If you depend on cheap, ever-expanding GPU and memory supply, build scenarios where capex growth flattens and per-unit prices stop falling—or rise.